Net sales grew +12% (cc 1, +11% USD) with core operating income 1 up +22% (cc, +19% USD) Sales growth driven by continued st ...
Zacks.com on MSN6d
Novartis Rises 5% Since Q4 Earnings: How Should You Play the Stock?Swiss pharma giant Novartis NVS reported better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates. Core earnings (excluding one-time charges) of $1.98 per ...
Investor's Business Daily on MSN12d
Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest MoneymakerNovartis stock rose Friday after the drugmaker beat fourth-quarter expectations, largely on the back of its heart failure drug Entresto.
Leqvio sales skyrocketed 83% to $223 million ... driven mainly by emerging growth markets. Novartis has a collaboration agreement with Roche RHHBY for Xolair. Novartis and Roche co-promote Xolair ...
Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...
Novartis expects profit and sales to grow further ... cholesterol treatment Leqvio and neuroscience medicine Kesimpta--offset a 1-percentage-point hit from generic competition.
Last week, Swiss pharma giant Novartis NVS reported better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates. Core earnings (excluding one-time charges ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback